Translational and Clinical Research Program

Siteman癌症中心（SCC）将卓越的临床研究，患者护理和基础科学相结合，以促进癌症的治疗。 环境中，新的解决方案开发癌症相关的健康问题。的结构 转化和临床研究计划旨在通过建立一个 恶性肿瘤基础科学、肿瘤学和肿瘤学研究者之间高效交流的基础设施 成像、预防和控制以及临床试验开发。在过去三年的奖励期间， 转化和临床研究计划为整合基础科学研究计划开发了一个范例 以疾病为导向的焦点小组，产生跨学科，高度转化的计划，最终将产生 多项目赠款，如计划项目赠款（P01）或SPORE。这一点可以通过 发展新命名的造血发展和造血计划，它已经团结了旧的干细胞 细胞生物学计划和白血病/淋巴瘤/移植焦点小组这个计划。的目标 转化和临床研究项目如下： 开发新的转化研究项目，最终产生多项目赠款（如 SPOREs和P01 s），通过将焦点小组与基础科学、预防和控制相结合， 和肿瘤成像计划。 开发，优先考虑和执行新的制药商发起的临床试验，特别强调 转化研究，涉及基础科学，预防和控制，以及 肿瘤成像计划，并由癌症遗传学，癌症，癌症， 生物学与发展、创新诊断和治疗以及化学预防。 参加重要的NCI申办的临床试验，解决只能在 多机构III期试验的设置。 与制药行业的成员合作，开发和测试新的化合物， SCC可以独特地提供药理学和分子专业知识。 开发多学科临床护理和研究计划，鼓励所有成员做出贡献 肿瘤学专业团体（治疗医生，基础科学研究人员，心理学家，护士， 等）。

The Siteman Cancer Center (SCC) combines excellence in clinical research, patient care and basic science to foster an environment in which novel solutions are developed for cancer-related health problems. The structure of the Translational and Clinical Research program is designed to maximize these discoveries by establishing an infrastructure for highly productive interchange between investigators in the basic science of malignancy, oncologic imaging, prevention and control and clinical trial development. During the previous three-year award period, the Translational and Clinical Research Program developed a paradigm for integrating basic science research programs with disease-oriented focus groups, producing interdisciplinary, highly translational programs that will ultimately produce multi-project grants, such as Program Project Grants (P01s) or SPOREs. This is demonstrated through the development of the newly-named Hematopoietic Development and Malignancy Program, which has united the old Stem Cell Biology Program and the Leukemia/Lymphoma/Transplant Focus Group of this program. The goals of the Translational and Clinical Research Program are as follows: ¿ To develop new translational research programs that will ultimately produce multi-project grants (such as SPOREs and P01s) through the integration of Focus Groups with the Basic Science, Prevention and Control, and Oncologic Imaging Programs. ¿ To develop, prioritize and execute novel investigator-initiated clinical trials with a particular emphasis on translational research that involves collaborators from the Basic Science, Prevention and Control, and Oncologic Imaging programs and is driven by the four central scientific themes of cancer genetics, cancer biology and development, innovative diagnostics and therapeutics, and chemoprevention. ¿ To participate in important NCI-sponsored clinical trials addressing questions that can only be answered in the setting of multi-institutional Phase III trials. ¿ To collaborate with members of the pharmaceutical industry to develop and test novel compounds that require pharmacologic and molecular expertise that can be uniquely provided by the SCC. ¿ To develop multidisciplinary clinical care and research programs that encourage contribution from all members of the oncology professional community (treating physicians, basic science researchers, psychologists, nurses, etc.).